LDE225 for Patients With PTCH1 or SMO Mutated Tumors
Phase 2
Terminated
- Conditions
- PTCH1 or SMO Activated Solid and Hematologic Tumors
- Interventions
- First Posted Date
- 2013-12-06
- Last Posted Date
- 2016-05-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 10
- Registration Number
- NCT02002689
- Locations
- 🇺🇸
Sanford Research Sanford Health, Sioux Falls, South Dakota, United States
🇺🇸University of California Davis Cancer Center UC Davis Cancer (3), Sacramento, California, United States
🇺🇸Cleveland Clinic Foundation Cleveland Clinic (19), Cleveland, Ohio, United States
Study of Efficacy and Safety of Vildagliptin as add-on Insulin Therapy in T2DM Patients
Phase 4
Completed
- Conditions
- Type 2 Diabetes Mellitus (T2DM)
- Interventions
- First Posted Date
- 2013-12-05
- Last Posted Date
- 2016-03-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 156
- Registration Number
- NCT02002221
- Locations
- 🇯🇵
Novartis Investigative Site, Suginami-ku, Tokyo, Japan
An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly
- Conditions
- Acromegaly
- First Posted Date
- 2013-11-27
- Last Posted Date
- 2015-12-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT01995734
- Locations
- 🇺🇸
The Johns Hopkins University School of Medicine Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Harbor-UCLA Medical Center Center for Men's Health, Torrance, California, United States
🇺🇸Sinai Hospital of Baltimore Sinai Hospital, Baltimore, Baltimore, Maryland, United States
Randomized, Double-blind, Placebo-controlled, Multicenter, Cross-over Study to Assess the Effects of a 3 Week Therapy Each With QVA149 Versus Placebo on Pulmonary Function and Average Physical Activity Levels in Patients With COPD.
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-11-27
- Last Posted Date
- 2016-04-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 194
- Registration Number
- NCT01996319
- Locations
- 🇩🇪
Novartis Investigative Site, Wiesloch, Germany
Study to Evaluate the Impact of the "PROactive Telecoaching Program" on Physical Activity in Patients With COPD.
Phase 4
Withdrawn
- Conditions
- COPD
- Interventions
- Device: Automated telehealth systemOther: Usual care
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2017-04-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT01992081
24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis
Phase 3
Completed
- Conditions
- Psoriatic Arthritis
- Interventions
- Biological: SecukinumabBiological: Placebo
- First Posted Date
- 2013-11-21
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 414
- Registration Number
- NCT01989468
- Locations
- 🇬🇧
Novartis Investigative Site, Tyne And Wear, United Kingdom
UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-vascular Endothelial Growth Factor (VEGF) Effects in Patients With neovascuLar Age-related Macular Degeneration (AMD)
Phase 4
Completed
- Conditions
- Neovacular Age-related Macular Degeneration
- Interventions
- Procedure: Neovascular Age-related Macular Degeneration
- First Posted Date
- 2013-11-20
- Last Posted Date
- 2017-05-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 205
- Registration Number
- NCT01988662
- Locations
- 🇹🇭
Novartis Investigative Site, Bangkok, Thailand
Safety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye
- First Posted Date
- 2013-11-19
- Last Posted Date
- 2019-07-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1049
- Registration Number
- NCT01986907
- Locations
- 🇮🇹
Novartis Investigative Site, Pozzuoli, Italy
Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen
Phase 4
Completed
- Conditions
- COPD
- Interventions
- Drug: SABADrug: LABADrug: SAMADrug: ICS
- First Posted Date
- 2013-11-15
- Last Posted Date
- 2019-03-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 4389
- Registration Number
- NCT01985334
- Locations
- 🇬🇧
Novartis Investigative Site, Wishaw, United Kingdom
Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure
Phase 2
Completed
- Conditions
- Chronic Heart Failure
- Interventions
- Drug: RLX030 (serelaxin)Drug: Placebo
- First Posted Date
- 2013-11-13
- Last Posted Date
- 2016-11-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 321
- Registration Number
- NCT01982292
- Locations
- 🇹🇷
Novartis Investigative Site, Sivas, Turkey